肾脏疾病与COVID-19患者院内死亡相关
这项前瞻性队列研究纳入武汉某三级教学医院及其三家分院共701例COVID-19住院患者,其中113例(16.1%)院内死亡。入院时蛋白尿占43.9%、血尿占26.7%,AKI发生率为5.1%;校正年龄、性别、疾病严重程度、合并症和白细胞计数后,基线肌酐升高、尿素氮升高、AKI分期、蛋白尿和血尿均为院内死亡的独立危险因素。
要点
- COVID-19患者入院时肾脏受累常见:蛋白尿43.9%、血尿26.7%。
- 住院期间AKI发生率为5.1%,且与院内死亡风险升高相关。
- 基线肌酐、尿素氮升高及蛋白尿、血尿是院内死亡的独立危险因素。
核心结论
- COVID-19患者入院时肾脏疾病患病率及住院期间AKI发生率较高,且与院内死亡相关。
研究设计与样本
- 前瞻性队列研究,纳入武汉某三级教学医院及其三家分院2020年疫情暴发期间住院的701例COVID-19患者,其中113例(16.1%)院内死亡。
- 患者中位年龄63岁(四分位距50-71),男性367例、女性334例。
主要发现
- 入院时蛋白尿占43.9%,血尿占26.7%。
- 血清肌酐升高、血尿素氮升高和eGFR低于60 ml/min/1.73m2的比例分别为14.4%、13.1%和13.1%。
- 研究期间AKI发生率为5.1%。
- Kaplan-Meier分析显示肾脏疾病患者院内死亡风险显著更高。
关键数值与推荐
- Cox回归校正年龄、性别、疾病严重程度、合并症和白细胞计数后,基线肌酐升高HR 2.10(95%CI 1.36-3.26)。
- 基线尿素氮升高HR 3.97(95%CI 2.57-6.14)。
- AKI 1期HR 1.90(95%CI 0.76-4.76),2期HR 3.51(95%CI 1.49-8.26),3期HR 4.38(95%CI 2.31-8.31)。
- 蛋白尿1+ HR 1.80(95%CI 0.81-4.00),2+~3+ HR 4.84(95%CI 2.00-11.70)。
- 血尿1+ HR 2.99(95%CI 1.39-6.42),2+~3+ HR 5.56(95%CI 2.58-12.01)。
临床怎么用
- 临床医生应提高对重症COVID-19患者肾脏疾病的认识,关注蛋白尿、血尿及肾功能指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m2 were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+∼3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+∼3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19.
引用
- Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020. PMID: 32247631. doi:10.1016/j.kint.2020.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。